Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.93 USD -5.85%
Market Cap: 85.4m USD
Have any thoughts about
Adagene Inc?
Write Note

Net Margin
Adagene Inc

-3 904.3%
Current
-1 137%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 904.3%
=
Net Income
-31.8m
/
Revenue
815.8k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CN
Adagene Inc
NASDAQ:ADAG
90.8m USD
-3 904%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country CN
Market Cap 90.8m USD
Net Margin
-3 904%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Adagene Inc
Glance View

Market Cap
85.4m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.96 USD
Overvaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 904.3%
=
Net Income
-31.8m
/
Revenue
815.8k
What is the Net Margin of Adagene Inc?

Based on Adagene Inc's most recent financial statements, the company has Net Margin of -3 904.3%.